Efficacy of Clozapine in Patients with Prolonged Methamphetamine Induced Psychotic Disorder: A Single-blind Comparison With Olanzapine

Efficacy of Clozapine in Patients with Prolonged Methamphetamine Induced Psychotic Disorder: A Single-blind Comparison With Olanzapine in drug abusers

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112225191N1

Enrollment

Registered

2016-01-17

Start date

2016-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant Psychosis Induced by Methamphetamine. This block contains a wide variety of disorders that differ in severity and clinical form but that are all related to the use of one or more drugs, which may or may not prescribe medicine. The third letter of the code identify the materials involved, and

Interventions

Intervention 1: In the first stage of a medical history and medical examination will be done and then the patient will be taken. Complete blood count tests Valktrvkardyvgram or ECG at baseline for all

Treatment - Drugs

In the first stage of a medical history and medical examination will be done and then the patient will be taken. Complete blood count tests Valktrvkardyvgram or ECG at baseline for all patients will b

In the first stage of a medical history and medical examination will be done and then the patient will be taken. CBC tests Valktrvkardyvgram or ECG at baseline for all patients will be performed. For

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- A psychotic disorder caused by prolonged use of methamphetamine (more than 1 month psychotic and at the same time cocaine has not); 2- obtaining the informed consent of the patient's guardian; 3- The absence of mental retardation (moderate or severe); 4- Non-organic neurological disease leading to clinical standpoint. Exclusion criteria: 1- If the loss of white blood cells or neutrophils less than 3,000 is less than 1,500; 2- Unwillingness to continue to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The severity of Symptoms and Psychosis Protests. Timepoint: Baseline, the end of the fourth week and eighth week. Method of measurement: Based on the PANSS Scale.;Craving. Timepoint: At baseline, the end of the fourth week and eighth week. Method of measurement: Craving Beliefs Questionnaire (CBQ.	—

Secondary

Measure	Time frame
Extrapyramidal Side Effects. Timepoint: Baseline, the end of the fourth week and eighth week. Method of measurement: Scale Extrapyramidal Side Effects ((ESRs.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Behnam Shariati

Iran University of Medical Sciences

behnamshariatimd@gmail.com+98 21 6435 2331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026